De-risking prostate cancer screening with ClarityDX Prostate
ClarityDX Prostate builds upon the utility of clinical features and blood-based biomarkers to determine a patient’s risk of having aggressive prostate cancer. This empowers patients and their healthcare providers make more informed healthcare decisions.
Dr. John Lewis
CEO of Nanostics and Bird Dogs Chair of Translational Oncology at the University of Alberta
Recent News
Breakthrough test provides clarity for prostate cancer diagnosis
With support from the Canadian Cancer Society, Dr John [...]
Nanostics Gets Featured on Global News
Prostate cancer is one of the most common cancers [...]
Research supporting ClarityDX Prostate published in Nature Digital Medicine
Published 26 June 2024 Development of an effective predictive [...]